GlassScriptPhysician profile
Ammar Haikal
NPI 1205248184
$8,330.01
in general payments reported to CMS, 2019-2025
26 companies · $487 in 2025
The $487 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $1,116 · 2021: $2,269 · 2022: $2,813 · 2023: $1,081 · 2024: $172 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,586 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.24 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,630.07 | 2019-2025 | Tavneos, Evenity, Enbrel |
| Abbvie INC. | $1,298.18 | 2019-2023 | |
| Horizon Therapeutics Plc | $821.16 | 2020-2023 | Krystexxa |
| Janssen Biotech, INC. | $785.56 | 2020-2025 | Simponi Aria, Tremfya, Remicade |
| Novartis Pharmaceuticals Corporation | $761.24 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $612.70 | 2019-2025 | Sotyktu |
| Pfizer INC. | $569.21 | 2019-2023 | |
| Lilly USA, LLC | $393.83 | 2019-2023 | Taltz |
| Glaxosmithkline, LLC. | $289.51 | 2019-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.65 | 2019-2023 | Ofev |
| Janssen Scientific Affairs, LLC | $227.00 | 2022 | |
| Aurinia Pharma U.S., INC. | $189.44 | 2021-2023 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $103.51 | 2021-2022 | |
| Ucb, INC. | $80.62 | 2019-2022 | |
| Octapharma USA, INC. | $80.23 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $74.32 | 2020 | |
| Fresenius Kabi USA, LLC | $30.00 | 2023 | |
| Mallinckrodt Hospital Products INC. | $29.17 | 2021-2023 | Acthar |
| Genzyme Corporation | $25.87 | 2019-2021 | |
| Genentech USA, INC. | $16.89 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.20 | 2019 | |
| Antares Pharma, INC. | $14.60 | 2020 | |
| Daiichi Sankyo INC. | $14.17 | 2020 | |
| Sobi, INC | $13.69 | 2023 | |
| Vanda Pharmaceuticals INC. | $12.86 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Haikal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.